Ostomy bags and Crohn's disease: what the TikTok gets right and wrong

What did @farmaceuticofernandez actually say?

Honestly, there is not much to work with here. The transcript provided captures only a garbled, incomplete fragment: "The next question is from the Today we will be seeing what's going on in this video." That is not a coherent medical claim. The video caption, however, tells a clearer story. The creator, a self-identified pharmacist, appears to explain what an ostomy bag is, why it is used in serious intestinal disease, and frames it as something that allows patients to "continue with their life." We will evaluate the caption's framing alongside what the category context suggests about peptide therapy connections.

The hashtags include both Crohn's disease and ulcerative colitis, which signals this video likely covers inflammatory bowel disease (IBD) broadly. That is fair territory for a pharmacist educator. Whether the clinical details hold up is a separate question.

Does the science back this up?

The basic premise, that some people with severe IBD require ostomy surgery, is well-supported. Studies are not ambiguous on this. Approximately 23 to 45 percent of Crohn's disease patients will require at least one surgery in their lifetime, and a meaningful subset of those will end up with a temporary or permanent stoma (Lichtenstein et al., 2018, American Journal of Gastroenterology). Ulcerative colitis patients face similar surgical realities, particularly those with medically refractory disease or toxic megacolon.

An ostomy, whether an ileostomy or colostomy, diverts waste through an opening in the abdominal wall called a stoma, with a pouching system attached externally. This is not controversial. The claim that it allows patients to "continue with their life" is also backed by quality-of-life research, though adjustment is real and often underplayed in short-form content (Scarpa et al., 2010, Colorectal Disease). Patients with well-managed ostomies report functional lives, but the psychosocial and physical adaptation period is significant and deserves mention.

What did they get wrong (or right)?

Based on the caption framing, the creator gets the foundational premise right. Ostomies are legitimate, often life-saving interventions for severe IBD. Calling it a "medical device that allows people to continue with their life" is accurate, if a bit simplified. That kind of accessible framing is genuinely useful for a 12-million-view audience that may never have heard the word ostomy before.

What is harder to evaluate, because the actual transcript is essentially unusable, is whether the creator correctly explained the difference between a colostomy and an ileostomy, whether they addressed reversibility, or whether they overstated Crohn's as the primary driver of ostomy use. Crohn's disease can affect any part of the GI tract, making ostomy outcomes different from UC cases. Conflating the two without nuance is a common educational shortcut that can mislead patients about their own prognosis.

• The caption does not mention that many ostomies in Crohn's are temporary.
• No mention of stoma care, which is a real patient burden.
• The peptide therapy category flag in this submission is worth naming: there is no established, FDA-approved peptide therapy for Crohn's disease or as an ostomy alternative. BPC-157 and similar peptides have shown some mucosal healing signals in animal models (Sikiric et al., 2016, Current Pharmaceutical Design), but this does not translate to clinical recommendations.

What should you actually know?

If you or someone you know has Crohn's disease, the possibility of surgery is not a failure of treatment. It is sometimes the most effective path forward. Biologics like anti-TNF agents have reduced surgical rates, but they have not eliminated the need for ostomies (Peyrin-Biroulet et al., 2011, Gut). A gastroenterologist and colorectal surgeon working together give you the best picture of where you stand.

On the peptide angle: BPC-157 is being discussed in optimization communities as a potential gut-healing compound. Animal studies show some promise in colitis models. However, no human clinical trials have confirmed safety or efficacy for IBD, no regulatory body has approved it for this use, and compounded peptide products are not equivalent to pharmaceutical-grade compounds studied in research. Do not let a viral video, or this fact-check, substitute for a conversation with a physician who knows your case.

• Talk to a gastroenterologist before making any treatment decisions based on social media content.
• If you are living with an ostomy, the United Ostomy Associations of America offers peer support and clinical resources.
• Surgical decisions in IBD involve your disease location, behavior, and response to medical therapy, not a one-size framework.